Health economics analysis for 18F-fluorodeoxyglucose positron-emission tomography compared with computed tomography in lung cancer.
10.11817/j.issn.1672-7347.2019.02.015
- Author:
Xiaohui ZENG
1
;
Peipei XU
1
;
Yunhua WANG
1
Author Information
1. PET-CT Center, Second Xiangya Hospital, Central South University, Changsha 410011, China.
- Publication Type:Journal Article
- MeSH:
Fluorodeoxyglucose F18;
Humans;
Lung Neoplasms;
Neoplasm Staging;
Positron Emission Tomography Computed Tomography;
Positron-Emission Tomography;
Radiopharmaceuticals;
Tomography, X-Ray Computed
- From:
Journal of Central South University(Medical Sciences)
2019;44(2):216-221
- CountryChina
- Language:Chinese
-
Abstract:
Compared with conventional imaging, 18F-fluorodeoxyglucose positron-emission tomography compared with computed tomography (18F-FDG PET/CT) possesses higher sensitivity and specificity in the diagnosis of solitary pulmonary nodule (SPN) and lung cancer. From the perspective of health economics, PET/CT is more suitable strategy for diagnose of SPN with intermediate probability of malignancy, and has good health economics value in preoperative staging diagnosis and follow-up after radiotherapy and chemotherapy of lung cancer. The evaluation method, effect index and comparison method used in the health economics research of PET/CT for lung cancer diagnosis and treatment are cost-effect analysis, life year and incremental cost-effect ratio, respectively. Case tracking and follow-up was a means of early studies on PET/CT health economics, and in recent years mathematical models are used in most studies.
